Geron gets regular review for imetelstat, disappointing investors

23 August 2023

fda_food_and_drug_administration_large-1

While Geron (Nasdaq: GERN) had hoped for a Priority Review for its rare blood cancer candidate imetelstat, the US regulator has confirmed a standard review will now take place, with a decision due by mid-June next year.

Further unnerving the market, the US Food and Drug Administration said it will also convene scientists for an advisory committee meeting as part of the review.

Investors shedded shares in the company following the announcement, softening Geron’s stock price to $2.28, a drop of around 13%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK